GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (STU:473A) » Definitions » Cyclically Adjusted FCF per Share

Adaptimmune Therapeutics (STU:473A) Cyclically Adjusted FCF per Share : €-0.84 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Adaptimmune Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2025 was €-0.244. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.84 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-07-01), Adaptimmune Therapeutics's current stock price is €0.20. Adaptimmune Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €-0.84. Adaptimmune Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Adaptimmune Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Adaptimmune Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics Cyclically Adjusted FCF per Share Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.76 -0.91

Adaptimmune Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.87 -0.85 -0.77 -0.91 -0.84

Competitive Comparison of Adaptimmune Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Adaptimmune Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptimmune Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Adaptimmune Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adaptimmune Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.244/136.1000*136.1000
=-0.244

Current CPI (Mar. 2025) = 136.1000.

Adaptimmune Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.000 100.100 0.000
201509 0.000 100.200 0.000
201512 0.000 100.400 0.000
201603 -0.270 100.400 -0.366
201606 -0.222 101.000 -0.299
201609 -0.220 101.500 -0.295
201612 -0.061 102.200 -0.081
201703 -0.535 102.700 -0.709
201706 -0.259 103.500 -0.341
201709 0.106 104.300 0.138
201712 -0.210 105.000 -0.272
201803 -0.426 105.100 -0.552
201806 -0.333 105.900 -0.428
201809 0.071 106.600 0.091
201812 -0.273 107.100 -0.347
201903 -0.316 107.000 -0.402
201906 -0.297 107.900 -0.375
201909 -0.259 108.400 -0.325
201912 -0.112 108.500 -0.140
202003 0.121 108.600 0.152
202006 -0.165 108.800 -0.206
202009 -0.094 109.200 -0.117
202012 -0.162 109.400 -0.202
202103 -0.259 109.700 -0.321
202106 -0.177 111.400 -0.216
202109 -0.255 112.400 -0.309
202112 0.736 114.700 0.873
202203 -0.357 116.500 -0.417
202206 -0.296 120.500 -0.334
202209 -0.361 122.300 -0.402
202212 -0.008 125.300 -0.009
202303 -0.223 126.800 -0.239
202306 -0.225 129.400 -0.237
202309 -0.188 130.100 -0.197
202312 -0.063 130.500 -0.066
202403 -0.123 131.600 -0.127
202406 0.167 133.000 0.171
202409 -0.193 133.500 -0.197
202412 -0.132 135.100 -0.133
202503 -0.244 136.100 -0.244

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Adaptimmune Therapeutics  (STU:473A) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Adaptimmune Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptimmune Therapeutics Business Description

Traded in Other Exchanges
Address
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics Headlines

No Headlines